Andreas von Deimling

List of Publications by Citations

673 papers	66,529 citations	115 h-index	240 g-index
735 ext. papers	82,965 ext. citations	8.4 avg, IF	7.47 L-index

#	Paper	IF	Citations
673	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathologica*, **2016**, 131, 803-20	14.3	8580
672	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
671	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, **2012**, 482, 226-31	50.4	1655
670	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37	24.3	1243
669	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature*, **2011**, 478, 197-203	50.4	1185
668	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
667	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathologica*, **2009**, 118, 469-74	14.3	874
666	Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathologica*, **2008**, 116, 597-602	14.3	786
665	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 397-405	14.3	771
664	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology* , **2021**, 23, 1231-1251	1	708
663	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. *Cancer Cell*, **2015**, 27, 728-43	24.3	672
662	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathologica*, **2012**, 124, 439-47	14.3	629
661	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. *Journal of Clinical Oncology*, **2009**, 27, 5874-80	2.2	625
660	Long-term survival with glioblastoma multiforme. *Brain*, **2007**, 130, 2596-606	11.2	624
659	Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5	50.4	623
658	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600
657	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathologica*, **2010**, 120, 707-18	14.3	596

656	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32	36.3	550
655	Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. *Cancer Research*, **2003**, 63, 1602-7	10.1	537
654	Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. *Journal of Neuro-Oncology*, **2007**, 81, 53-60	4.8	533
653	Subsets of glioblastoma multiforme defined by molecular genetic analysis. *Brain Pathology*, **1993**, 3, 19-26	6	520
652	Brain tumour cells interconnect to a functional and resistant network. *Nature*, **2015**, 528, 93-8	50.4	496
651	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072	36.2	483
650	A vaccine targeting mutant IDH1 induces antitumour immunity. *Nature*, **2014**, 512, 324-7	50.4	481
649	Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell*, **2013**, 24, 660-72	24.3	478
648	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472
647	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
646	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood*, **2012**, 120, 2700-3	2.2	469
645	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. *Journal of Clinical Oncology*, **2009**, 27, 5743-50	2.2	464
644	Lomustine and Bevacizumab in Progressive Glioblastoma. *New England Journal of Medicine*, **2017**, 377, 1954-1963	59.2	425
643	EANO guidelines for the diagnosis and treatment of meningiomas. *Lancet Oncology, The*, **2016**, 17, e383-91	21.7	414
642	Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathology*, **2010**, 20, 245-54	6	410
641	International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathology*, **2014**, 24, 429-35	6	408
640	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. *Acta Neuropathologica*, **2011**, 122, 11-9	14.3	399
639	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57	24.3	395

638	Actively personalized vaccination trial for newly diagnosed glioblastoma. *Nature*, **2019**, 565, 240-245	50.4	388
637	DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. *Nature Genetics*, **1997**, 17, 32-9	36.3	386
636	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. *Nature*, **2014**, 511, 428-34	50.4	377
635	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". *Acta Neuropathologica*, **2018**, 136, 805-810	14.3	367
634	Glioblastoma: pathology, molecular mechanisms and markers. *Acta Neuropathologica*, **2015**, 129, 829-48	14.3	360
633	The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. *Journal of Neuro-Oncology*, **2006**, 78, 7-14	4.8	354
632	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncology, The*, **2017**, 18, 682-694	21.7	336
631	Monoclonal antibody specific for IDH1 R132H mutation. *Acta Neuropathologica*, **2009**, 118, 599-601	14.3	330
630	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, **2016**, 29, 379-393	24.3	319
629	MGMT testing--the challenges for biomarker-based glioma treatment. *Nature Reviews Neurology*, **2014**, 10, 372-85	15	316
628	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathologica*, **2015**, 129, 133-46	14.3	313
627	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncology, The*, **2016**, 17, 1521-1532	21.7	294
626	A new clinico-pathological classification system for mesial temporal sclerosis. *Acta Neuropathologica*, **2007**, 113, 235-44	14.3	283
625	Histone deacetylase 8 in neuroblastoma tumorigenesis. *Clinical Cancer Research*, **2009**, 15, 91-9	12.9	278
624	PTEN mutations in gliomas and glioneuronal tumors. *Oncogene*, **1998**, 16, 2259-64	9.2	267
623	Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. *Journal of Neuropathology and Experimental Neurology*, **1995**, 54, 91-5	3.1	266
622	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. *American Journal of Surgical Pathology*, **2013**, 37, 61-5	6.7	254
621	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. *Acta Neuropathologica*, **2013**, 125, 651-8	14.3	247

620	Yes and PI3K bind CD95 to signal invasion of glioblastoma. *Cancer Cell*, **2008**, 13, 235-48	24.3	245
619	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. *Acta Neuropathologica*, **2013**, 126, 443-51	14.3	239
618	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. *Acta Neuropathologica*, **2009**, 118, 401-5	14.3	223
617	Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF- *Clinical Cancer Research*, **2011**, 17, 4296-308	12.9	222
616	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathologica*, **2015**, 129, 669-78	14.3	220
615	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathologica*, **2013**, 126, 907-15	14.3	211
614	Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15553-8	11.5	210
613	Molecular pathways in the formation of gliomas. *Glia*, **1995**, 15, 328-38	9	209
612	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. *Acta Neuropathologica*, **2015**, 129, 679-93	14.3	208
611	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. *Nature Reviews Clinical Oncology*, **2021**, 18, 170-186	19.4	204
610	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. *Acta Neuropathologica*, **2017**, 133, 5-12	14.3	202
609	Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. *American Journal of Pathology*, **1999**, 155, 627-32	5.8	202
608	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathologica*, **2014**, 128, 551-9	14.3	200
607	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. *Acta Neuropathologica*, **2015**, 129, 867-73	14.3	200
606	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathology*, **2020**, 30, 844-856	6	196
605	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathologica*, **2015**, 130, 407-17	14.3	194
604	The retinoblastoma gene is involved in malignant progression of astrocytomas. *Annals of Neurology* , **1994**, 36, 714-21	9.4	193
603	TERT Promoter Mutations and Risk of Recurrence in Meningioma. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	189

602	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. *Oncotarget*, **2014**, 5, 1038-51	3.3	189
601	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *European Journal of Cancer*, **2016**, 65, 91-101	7.5	186
600	Molecular genetic evidence for subtypes of oligoastrocytomas. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 1098-104	3.1	185
599	IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. *Scientific Reports*, **2015**, 5, 16238	4.9	182
598	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro-Oncology*, **2020**, 22, 1073-1113	1	178
597	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. *Acta Neuropathologica*, **2012**, 123, 223-33	14.3	178
596	Comparative study of p53 gene and protein alterations in human astrocytic tumors. *Journal of Neuropathology and Experimental Neurology*, **1993**, 52, 31-8	3.1	178
595	Central neurocytoma: histopathological variants and therapeutic approaches. *Journal of Neurosurgery*, **1992**, 76, 32-7	3.2	178
594	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. *Radiology*, **2016**, 281, 907-918	20.5	177
593	Molecular staging of intracranial ependymoma in children and adults. *Journal of Clinical Oncology*, **2010**, 28, 3182-90	2.2	177
592	Targeting the BRAF V600E mutation in multiple myeloma. *Cancer Discovery*, **2013**, 3, 862-9	24.4	176
591	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 763-74	14.3	176
590	Adult medulloblastoma comprises three major molecular variants. *Journal of Clinical Oncology*, **2011**, 29, 2717-23	2.2	176
589	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nature Medicine*, **2018**, 24, 1192-1203	50.5	174
588	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. *Blood*, **2012**, 120, e28-34	2.2	172
587	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathologica*, **2020**, 139, 603-608	14.3	170
586	Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. *American Journal of Surgical Pathology*, **2012**, 36, 844-50	6.7	163
585	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166	14.3	162

584	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. *Lancet Oncology, The*, **2019**, 20, 728-740	21.7	160
583	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. *Neurology*, **2013**, 81, 1515-22	6.5	160
582	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. *Acta Neuropathologica*, **2013**, 125, 351-8	14.3	158
581	Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. *Journal of Neurosurgery*, **1992**, 77, 295-301	3.2	158
580	Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. *American Journal of Pathology*, **2002**, 161, 313-9	5.8	157
579	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica*, **2014**, 128, 279-89	14.3	152
578	HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. *Clinical Cancer Research*, **2010**, 16, 3240-52	12.9	152
577	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. *Acta Neuropathologica*, **2016**, 131, 903-10	14.3	151
576	Impact of genotype and morphology on the prognosis of glioblastoma. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 321-8	3.1	151
575	A role for beta-melanocyte-stimulating hormone in human body-weight regulation. *Cell Metabolism* , **2006**, 3, 141-6	24.6	149
574	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathologica*, **2014**, 128, 561-71	14.3	148
573	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. *Acta Neuropathologica*, **2018**, 136, 181-210	14.3	148
572	Molecular markers in low-grade gliomas: predictive or prognostic?. *Clinical Cancer Research*, **2011**, 17, 4588-99	12.9	145
571	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. *Acta Neuropathologica*, **2013**, 125, 891-900	14.3	144
570	Brain metastases: pathobiology and emerging targeted therapies. *Acta Neuropathologica*, **2012**, 123, 205-22	14.3	133
569	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. *Molecular Therapy*, **2017**, 25, 2620-2634	11.7	130
568	Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. *International Journal of Cancer*, **1998**, 79, 640-4	7.5	130
567	Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. *Journal of Molecular Diagnostics*, **2013**, 15, 94-100	5.1	129

566	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 409-14	11.5	126
565	The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. *Brain Pathology*, **2011**, 21, 74-87	6	126
564	FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. *Journal of Clinical Oncology*, **2011**, 29, 3852-61	2.2	125
563	Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. *Clinical Cancer Research*, **2013**, 19, 5146-57	12.9	120
562	Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?. *Clinical Cancer Research*, **2007**, 13, 6933-7	12.9	119
561	CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. *Acta Neuropathologica*, **2012**, 123, 853-60	14.3	116
560	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. *Acta Neuropathologica*, **2017**, 133, 629-644	14.3	115
559	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
558	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. *Acta Neuropathologica*, **2010**, 120, 253-60	14.3	115
557	Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. *American Journal of Surgical Pathology*, **2012**, 36, 1796-800	6.7	114
556	Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. *Journal of Neuropathology and Experimental Neurology*, **2000**, 59, 544-58	3.1	114
555	BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. *American Journal of Surgical Pathology*, **2013**, 37, 1592-602	6.7	112
554	Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. *Journal of Neurosurgery*, **2000**, 92, 983-90	3.2	112
553	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. *Neuro-Oncology*, **2018**, 20, 848-857	1	111
552	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. *Acta Neuropathologica*, **2011**, 121, 241-52	14.3	111
551	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathologica*, **2016**, 131, 877-87	14.3	110
550	Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. *Neuroscience Letters*, **2002**, 324, 105-8	3.3	110
549	Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. *Journal of Clinical Oncology*, **2010**, 28, 3054-60	2.2	109

548	Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 859-64	4	107
547	Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. *Cell Cycle*, **2013**, 12, 1637-8	4.7	106
546	IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. *Seizure: the Journal of the British Epilepsy Association*, **2012**, 21, 194-7	3.2	105
545	Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. *American Journal of Surgical Pathology*, **2010**, 34, 1199-204	6.7	105
544	Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. *Glia*, **2001**, 35, 167-79	9	103
543	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. *Acta Neuropathologica*, **2016**, 131, 137-46	14.3	102
542	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathologica*, **2018**, 136, 793-803	14.3	102
541	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. *Acta Neuropathologica Communications*, **2016**, 4, 20	7.3	101
540	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. *Acta Neuropathologica*, **2018**, 136, 273-291	14.3	99
539	Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. *Neuro-Oncology*, **2009**, 11, 122-31	1	99
538	Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. *Journal of Neurotrauma*, **2006**, 23, 1518-28	5.4	99
537	Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. *Modern Pathology*, **2015**, 28, 187-200	9.8	97
536	Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. *Journal of Neuropathology and Experimental Neurology*, **2001**, 60, 917-20	3.1	97
535	Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. *Oncogene*, **1997**, 14, 611-6	9.2	96
534	Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. *PLoS ONE*, **2012**, 7, e33449	3.7	96
533	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. *Clinical Cancer Research*, **2017**, 23, 6846-6855	12.9	94
532	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. *EMBO Journal*, **2012**, 31, 2629-47	13	93
531	Addressing diffuse glioma as a systemic brain disease with single-cell analysis. *Archives of Neurology* , **2012**, 69, 523-6		93

530	Evolutionary Trajectories of IDH Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. *Cancer Cell*, **2019**, 35, 692-704.e12	24.3	92
529	Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. *Acta Neuropathologica*, **2009**, 117, 457-64	14.3	91
528	The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. *Cancer Research*, **2013**, 73, 3225-34	10.1	90
527	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. *International Journal of Cancer*, **2014**, 135, 1822-31	7.5	89
526	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. *Clinical Cancer Research*, **2014**, 20, 6304-13	12.9	89
525	Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. *Human Mutation*, **2004**, 23, 134-46	4.7	89
524	Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. *American Journal of Surgical Pathology*, **2013**, 37, 413-20	6.7	88
523	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). *Acta Neuropathologica*, **2012**, 124, 875-81	14.3	87
522	Molecular genetics of pediatric brain stem gliomas. Application of PCR techniques to small and archival brain tumor specimens. *Journal of Neuropathology and Experimental Neurology*, **1993**, 52, 507-15	3.1	86
521	Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. *Acta Neuropathologica*, **1993**, 86, 81-5	14.3	86
520	A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. *Oncogene*, **1998**, 16, 2403-6	9.2	84
519	Molecular pathogenesis of oligodendroglial tumors. *Journal of Neuro-Oncology*, **2004**, 70, 161-81	4.8	84
518	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, **2020**, 182, 1252-1270.e34	56.2	84
517	Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. *Histopathology*, **2014**, 65, 613-22	7.3	83
516	TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. *Journal of Clinical Oncology*, **2010**, 28, 5188-96	2.2	83
515	MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. *Human Molecular Genetics*, **1994**, 3, 1841-5	5.6	83
514	Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. *Cancer Research*, **2009**, 69, 416-21	10.1	82
513	Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. *Acta Neuropathologica*, **2009**, 117, 445-56	14.3	82

512	BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. *International Journal of Cancer*, **2013**, 133, 1624-30	7.5	81
511	Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 428-32	8.8	80
510	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *Neuro-Oncology*, **2016**, 18, 1529-1537	1	80
509	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. *Neuro-Oncology*, **2019**, 21, 901-910	1	79
508	Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. *Radiation Oncology*, **2011**, 6, 115	4.2	79
507	Deletion mapping of chromosome 19 in human gliomas. *International Journal of Cancer*, **1994**, 57, 676-80	7.5	79
506	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. *Neuro-Oncology*, **2019**, 21, ii81-ii82	1	78
505	LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA. *Neuro-Oncology*, **2019**, 21, ii101-ii102	1	78
504	LGG-04. CHARACTERIZATION OF ONCOGENE-INDUCED SENESCENCE AND THE ROLE OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2017**, 19, iv33-iv33	1	78
503	TRTH-09. PTT2.0: DEVELOPING PERSONALIZED PEDIATRIC ONCOLOGY. *Neuro-Oncology*, **2017**, 19, iv53-iv53	1	78
502	LGG-20. MOLECULARLY-DEFINED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) COMPRISES TWO SUBGROUPS WITH DISTINCT CLINICAL AND GENETIC FEATURES. *Neuro-Oncology*, **2018**, 20, i108-i108	1	78
501	ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. *Neuro-Oncology*, **2015**, 17, v42.3-v42	1	78
500	GENE-07. MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. *Neuro-Oncology*, **2017**, 19, iv19-iv19	1	78
499	MNGI-02. PREOPERATIVE EMBOLIZATION OF MENINGIOMA: INFERIOR NEUROLOGICAL OUTCOME, INCREASED RISK OF CARDIOVASCULAR COMPLICATIONS AND SHORTER TIME TO RECURRENCE?. *Neuro-Oncology*, **2017**, 19, vi132-vi132	1	78
498	NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101. *Neuro-Oncology*, **2017**, 19, vi153-vi153	1	78
497	PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. *Neuro-Oncology*, **2017**, 19, vi175-vi176	1	78
496	PDTM-47. CHARACTERIZATION OF THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA AND ITS ROLE IN ONCOGENE-INDUCED SENESCENCE. *Neuro-Oncology*, **2017**, 19, vi200-vi200	1	78
495	SURG-16PROGNOSTIC VALUE OF THE EXTENT OF RESECTION AND IDH1 MUTATION STATUS IN WHO GRADE II ASTROCYTOMAS. *Neuro-Oncology*, **2015**, 17, v217.4-v217	1	78

494	IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. *Neuro-Oncology*, **2018**, 20, vi133-vi133	1	78
493	QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA □RESULTS OF THE HIT2000 TRIAL. *Neuro-Oncology*, **2020**, 22, iii433-iii433	1	78
492	MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS. *Neuro-Oncology*, **2020**, 22, iii413-iii413	1	78
491	PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS. *Neuro-Oncology*, **2020**, 22, iii425-iii425	1	78
490	PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS. *Neuro-Oncology*, **2020**, 22, iii429-iii430	1	78
489	LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE. *Neuro-Oncology*, **2020**, 22, iii372-iii373	1	78
488	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. *Neuro-Oncology*, **2020**, 22, iii311-iii311	1	78
487	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. *Neuro-Oncology*, **2020**, 22, iii388-iii388	1	78
486	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). *Neuro-Oncology*, **2020**, 22, iii410-iii410	1	78
485	PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS□THE MNP 2.0 STUDY. *Neuro-Oncology*, **2020**, 22, iii426-iii426	1	78
484	EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY. *Neuro-Oncology*, **2021**, 23, i10-i10	1	78
483	EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. *Neuro-Oncology*, **2021**, 23, i47-i48	1	78
482	EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. *Neuro-Oncology*, **2021**, 23, i13-i14	1	78
481	LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. *Neuro-Oncology*, **2016**, 18, iii84.3-iii84	1	78
480	TB-11MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. *Neuro-Oncology*, **2016**, 18, iii170.4-iii170	1	78
479	TB-14THE INFORM PERSONALIZED MEDICINE STUDY - NEW MOLECULAR INSIGHTS INTO RELAPSED PEDIATRIC BRAIN TUMORS. *Neuro-Oncology*, **2016**, 18, iii171.1-iii171	1	78
478	HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2016**, 18, iii63.2-iii63	1	78
477	TBIO-10. PEDIATRIC TARGETED THERAPY 2.0: DEVELOPMENT OF PERSONALIZED PEDIATRIC ONCOLOGY. *Neuro-Oncology*, **2018**, 20, i182-i182	1	78

476	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. *Neuro-Oncology*, **2018**, 20, vi48-vi49	1	78
475	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2018**, 20, i106-i106	1	78
474	TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICS THE PROSPECTIVE MNP2.0 STUDY. *Neuro-Oncology*, **2018**, 20, i181-i181	1	78
473	MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY. *Neuro-Oncology*, **2018**, 20, i121-i121	1	78
472	The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. *Molecular Cancer Therapeutics*, **2008**, 7, 3566-74	6.1	77
471	Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. *Carcinogenesis*, **2006**, 27, 664-71	4.6	76
470	BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. *Annals of the Rheumatic Diseases*, **2015**, 74, 1596-602	2.4	75
469	Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 606-12	3.1	75
468	Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes. *American Journal of Surgical Pathology*, **2013**, 37, 193-9	6.7	74
467	Sarcoma classification by DNA methylation profiling. *Nature Communications*, **2021**, 12, 498	17.4	74
466	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. *International Journal of Cancer*, **2014**, 134, 2437-47	7.5	73
465	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. *Acta Neuropathologica*, **2018**, 136, 239-253	14.3	73
464	Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. *Journal of the National Cancer Institute*, **2013**, 105, 917-9	9.7	72
463	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. *Neuropathology and Applied Neurobiology*, **2015**, 41, 694-720	5.2	72
462	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Modern Pathology*, **2014**, 27, 1028-34	9.8	72
461	Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. *Human Pathology*, **2013**, 44, 329-35	3.7	72
460	Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. *International Journal of Cancer*, **2001**, 94, 218-21	7.5	72
459	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. *Acta Neuropathologica*, **2017**, 134, 507-516	14.3	70

458	2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. *International Journal of Cancer*, **2012**, 131, 766-8	7.5	70
457	PIK3CA mutations in glioblastoma multiforme. *Acta Neuropathologica*, **2005**, 109, 639-42	14.3	70
456	IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. *Cancer Research*, **2016**, 76, 7118-7129	10.1	70
455	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chromosomes and Cancer*, **2000**, 29, 16-25	5	70
454	The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. *EMBO Molecular Medicine*, **2012**, 4, 38-51	12	69
453	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. *Acta Neuropathologica*, **2013**, 126, 757-62	14.3	69
452	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. *Acta Neuropathologica*, **2012**, 123, 841-52	14.3	68
451	A vaccine targeting mutant IDH1 in newly diagnosed glioma. *Nature*, **2021**, 592, 463-468	50.4	68
450	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. *Journal of Neuroimmunology*, **2013**, 265, 106-16	3.5	67
449	Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 729-36	3.1	66
448	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. *Acta Neuropathologica Communications*, **2017**, 5, 39	7.3	65
447	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. *Brain Pathology*, **2018**, 28, 656-662	6	65
446	Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. *Brain Pathology*, **2000**, 10, 85-92	6	65
445	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. *Cancer Discovery*, **2020**, 10, 942-963	24.4	65
444	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. *International Journal of Cancer*, **2011**, 128, 1095-103	7.5	64
443	Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. *Human Pathology*, **1992**, 23, 1402-9	3.7	64
442	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. *Acta Neuropathologica*, **2018**, 136, 327-337	14.3	63
441	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. *Acta Neuropathologica*, **2011**, 122, 637-50	14.3	63

440	Tweety-Homolog 1 Drives Brain Colonization of Gliomas. *Journal of Neuroscience*, **2017**, 37, 6837-6850	6.6	62
439	Clonality of multiple meningiomas. *Journal of Neurosurgery*, **1997**, 86, 853-8	3.2	62
438	Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. *Journal of Neuro-Oncology*, **2007**, 82, 187-92	4.8	62
437	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. *Acta Neuropathologica*, **2018**, 135, 955-963	14.3	61
436	BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. *Brain Pathology*, **2014**, 24, 221-9	6	61
435	R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. *Acta Neuropathologica*, **2011**, 121, 279-81	14.3	61
434	Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. *Cancer Research*, **2010**, 70, 8003-14	10.1	61
433	Carbon ion radiation therapy for high-risk meningiomas. *Radiotherapy and Oncology*, **2010**, 95, 54-9	5.3	60
432	Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. *International Journal of Cancer*, **2006**, 119, 792-800	7.5	60
431	Gliomatosis cerebri: no evidence for a separate brain tumor entity. *Acta Neuropathologica*, **2016**, 131, 309-319	14.3	59
430	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. *Neuro-Oncology*, **2014**, 16, 1630-8	7	59
429	Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. *Journal of Neurosurgery*, **1996**, 85, 634-41	3.2	59
428	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. *Modern Pathology*, **2018**, 31, 1246-1256	9.8	58
427	Diagnostic challenges in meningioma. *Neuro-Oncology*, **2017**, 19, 1588-1598	1	57
426	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. *Nature Communications*, **2020**, 11, 931	17.4	57
425	TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. *Journal of Experimental and Clinical Cancer Research*, **2014**, 33, 33	12.8	57
424	D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. *Acta Neuropathologica Communications*, **2014**, 2, 19	7.3	57
423	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 515-27	14.3	57

422	EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. *Neuro-Oncology*, **2008**, 10, 946-57	1	56
421	Targeted Genomic Profiling of Acral Melanoma. *Journal of the National Cancer Institute*, **2019**, 111, 1068-1077	9.7	55
420	Evidence of H3 K27M mutations in posterior fossa ependymomas. *Acta Neuropathologica*, **2016**, 132, 635-7	14.3	55
419	Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. *Neuro-Oncology*, **2014**, 16, 914-23	1	55
418	Imaging and diagnostic advances for intracranial meningiomas. *Neuro-Oncology*, **2019**, 21, i44-i61	1	55
417	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro-Oncology*, **2019**, 21, 95-105	1	55
416	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. *Acta Neuropathologica*, **2018**, 135, 601-615	14.3	54
415	Interlaboratory comparison of IDH mutation detection. *Journal of Neuro-Oncology*, **2013**, 112, 173-8	4.8	54
414	Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. *Brain Pathology*, **2015**, 25, 202-8	6	54
413	PCR- and restriction endonuclease-based detection of IDH1 mutations. *Brain Pathology*, **2010**, 20, 298-300	6	53
412	MYCN amplification drives an aggressive form of spinal ependymoma. *Acta Neuropathologica*, **2019**, 138, 1075-1089	14.3	51
411	Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. *Thyroid*, **2014**, 24, 858-66	6.2	51
410	Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. *Journal of Neurology*, **2000**, 247, 455-60	5.5	51
409	Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 881-5	3.1	51
408	IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2569-2580	8.8	50
407	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. *Lung Cancer*, **2014**, 83, 83-9	5.9	50
406	No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. *Journal of Neuro-Oncology*, **2012**, 109, 15-22	4.8	50
405	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. *Lung Cancer*, **2013**, 80, 278-83	5.9	50

404	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. *Apoptosis: an International Journal on Programmed Cell Death*, **2013**, 18, 1416-1425	5.4	50
403	Chromosomal imbalances in brain metastases of solid tumors. *Brain Pathology*, **2000**, 10, 395-401	6	50
402	NF2 mutations in secretory and other rare variants of meningiomas. *Brain Pathology*, **2006**, 16, 15-9	6	50
401	Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. *Journal of Pathology*, **2001**, 194, 81-7	9.4	50
400	The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. *Cancer Genetics and Cytogenetics*, **1996**, 88, 136-40		50
399	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. *Acta Neuropathologica Communications*, **2019**, 7, 24	7.3	49
398	Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. *Journal of the American Academy of Dermatology*, **2012**, 67, 488-91	4.5	49
397	Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. *Journal of Neuro-Oncology*, **2003**, 65, 107-18	4.8	49
396	Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. *Acta Neuropathologica*, **2012**, 124, 883-91	14.3	48
395	Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. *Clinical Cancer Research*, **2009**, 15, 5457-65	12.9	48
394	MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. *Neoplasia*, **2007**, 9, 671-7	6.4	48
393	Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. *Journal of Neuropathology and Experimental Neurology*, **2002**, 61, 1092-9	3.1	48
392	Hereditary tumor syndromes of the nervous system: overview and rare syndromes. *Brain Pathology*, **1995**, 5, 145-51	6	48
391	K27M-mutant histone-3 as a novel target for glioma immunotherapy. *OncoImmunology*, **2017**, 6, e1328340	7.2	47
390	Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report. *Journal of Neurosurgery*, **2001**, 95, 138-42	3.2	47
389	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. *Acta Neuropathologica Communications*, **2015**, 3, 22	7.3	46
388	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. *Neuro-Oncology*, **2016**, 18, 790-6	1	46
387	Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. *Archives of Pathology and Laboratory Medicine*, **2014**, 138, 71-5	5	46

386	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. *Acta Neuropathologica*, **2014**, 128, 879-91	14.3	46
385	Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 1415-21	4	46
384	Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. *BMC Cancer*, **2008**, 8, 61	4.8	46
383	Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. *Acta Neuropathologica*, **2001**, 102, 69-74	14.3	46
382	The molecular landscape of ETMR at diagnosis and relapse. *Nature*, **2019**, 576, 274-280	50.4	46
381	Molecular and translational advances in meningiomas. *Neuro-Oncology*, **2019**, 21, i4-i17	1	46
380	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. *Nature Communications*, **2017**, 8, 186	17.4	45
379	Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. *Brain Pathology*, **2012**, 22, 26-31	6	45
378	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. *Neuro-Oncology*, **2013**, 15, 1405-12	1	45
377	DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. *Brain Pathology*, **2007**, 17, 363-70	6	45
376	Molecular genetic analysis of oligodendroglial tumors. *Journal of Neuropathology and Experimental Neurology*, **2005**, 64, 10-4	3.1	45
375	Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. *Acta Neuropathologica*, **2004**, 107, 159-68	14.3	45
374	Advances in multidisciplinary therapy for meningiomas. *Neuro-Oncology*, **2019**, 21, i18-i31	1	44
373	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and □KG. *Acta Neuropathologica Communications*, **2013**, 1, 18	7.3	44
372	RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. *Brain Pathology*, **2009**, 19, 279-92	6	44
371	Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. *Cancer Letters*, **2007**, 250, 107-16	9.9	42
370	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. *Acta Neuropathologica*, **2015**, 130, 419-34	14.3	41
369	Protein kinase C□as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 14735-40	11.5	41

368	Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. *International Journal of Cancer*, **2011**, 128, 1981-8	7.5	41
367	Estimating cancer survival and clinical outcome based on genetic tumor progression scores. *Bioinformatics*, **2005**, 21, 2438-46	7.2	41
366	BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. *Neuropathology and Applied Neurobiology*, **2015**, 41, 733-42	5.2	40
365	Identification of diagnostic serum protein profiles of glioblastoma patients. *Journal of Neuro-Oncology*, **2011**, 102, 71-80	4.8	40
364	Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 670-6	4	40
363	Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. *Acta Neuropathologica*, **2010**, 120, 261-7	14.3	40
362	Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. *Neuro-Oncology*, **2007**, 9, 291-7	1	40
361	CIC protein instability contributes to tumorigenesis in glioblastoma. *Nature Communications*, **2019**, 10, 661	17.4	39
360	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. *Glia*, **2015**, 63, 78-90	9	39
359	Incidence, mortality and outcome of meningiomas: A population-based study from Germany. *Cancer Epidemiology*, **2019**, 62, 101562	2.8	39
358	Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. *Journal of Pathology*, **2014**, 234, 23-33	9.4	39
357	Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. *Modern Pathology*, **2014**, 27, 135-44	9.8	39
356	Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. *American Journal of Pathology*, **2005**, 166, 1773-9	5.8	39
355	Pathology and molecular genetics of oligodendroglial tumors. *Journal of Molecular Medicine*, **2004**, 82, 638-55	5.5	39
354	Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 422-425	3.1	38
353	Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1-mutation as common tumor initiating event. *PLoS ONE*, **2012**, 7, e41298	3.7	38
352	Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. *Neoplasia*, **2005**, 7, 883-93	6.4	38
351	GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. *Cancer Research*, **2014**, 74, 2604-16	10.1	37

350	Subclassification of nerve sheath tumors by gene expression profiling. *Brain Pathology*, **2004**, 14, 258-646		37
349	Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. *Journal of Neurochemistry*, **2016**, 136, 1142-1154	6	37
348	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. *Acta Neuropathologica*, **2019**, 138, 497-504	14.3	36
347	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathology*, **2017** , 27, 851-852	6	36
346	Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. *Glia*, **2011**, 59, 1200-4	9	36
345	The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. *Genes Chromosomes and Cancer*, **2002**, 35, 242-55	5	36
344	Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. *Human Genetics*, **2000**, 107, 350-6	6.3	36
343	DNA methylation-based reclassification of olfactory neuroblastoma. *Acta Neuropathologica*, **2018**, 136, 255-271	14.3	35
342	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. *Neuro-Oncology*, **2018**, 20, 367-379	1	35
341	Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. *PLoS ONE*, **2014**, 9, e86194	3.7	35
340	Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression. *Journal of Neuro-Oncology*, **2011**, 105, 219-24	4.8	35
339	A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes. *Brain Pathology*, **1998**, 8, 13-8	6	35
338	Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. *Journal of Neuropathology and Experimental Neurology*, **1995**, 54, 622-6	3.1	35
337	Location of N-methyl-N'-nitro-N-nitrosoguanidine-induced gastrointestinal tumors correlates with thiol distribution. *Carcinogenesis*, **1983**, 4, 879-83	4.6	35
336	Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. *PLoS ONE*, **2012**, 7, e47663	3.7	35
335	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. *Oncotarget*, **2015**, 6, 31050-68	3.3	35
334	Hereditary tumor syndromes and gliomas. *Recent Results in Cancer Research*, **2009**, 171, 83-102	1.5	35
333	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. *Acta Neuropathologica*, **2020**, 139, 193-209	14.3	35

332	Nestin expression identifies ependymoma patients with poor outcome. *Brain Pathology*, **2012**, 22, 848-66	6	34
331	A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. *PLoS ONE*, **2013**, 8, e59773	3.7	34
330	The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. *European Journal of Cardio-thoracic Surgery*, **2011**, 39, 968-73	3	34
329	Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. *European Journal of Haematology*, **2010**, 85, 457-9	3.8	34
328	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. *Nature Protocols*, **2020**, 15, 479-512	18.8	34
327	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. *Journal of Clinical Oncology*, **2018**, JCO2017764720	2.2	34
326	Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. *Acta Neuropathologica*, **2014**, 127, 565-72	14.3	33
325	Impaired Pten expression in human malignant peripheral nerve sheath tumours. *PLoS ONE*, **2012**, 7, e47595	3.7	33
324	Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. *Clinical and Experimental Metastasis*, **2007**, 24, 57-66	4.7	33
323	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. *Neuro-Oncology*, **2019**, 21, i32-i43	1	33
322	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. *Neuro-Oncology*, **2018**, 20, 1616-1624	1	32
321	Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. *Neuro-Oncology*, **2009**, 11, 803-18	1	32
320	Loss of Mpdz impairs ependymal cell integrity leading to perinatal-onset hydrocephalus in mice. *EMBO Molecular Medicine*, **2017**, 9, 890-905	12	31
319	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. *Journal of the National Cancer Institute*, **2017**, 109, 1-4	9.7	31
318	The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination. *PLoS ONE*, **2011**, 6, e21065	3.7	31
317	Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. *International Journal of Cancer*, **1998**, 78, 306-9	7.5	31
316	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. *BMC Cancer*, **2016**, 16, 81	4.8	30
315	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. *Clinical Sarcoma Research*, **2017**, 7, 9	2.5	30

314	Mutational analysis of INI1 in sporadic human brain tumors. *Acta Neuropathologica*, **2001**, 101, 479-82	14.3	30
313	TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. *Journal of Neuro-Oncology*, **2001**, 52, 263-72	4.8	30
312	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1273-1281	4.9	29
311	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. *Neuropathology*, **2015**, 35, 538-44	2	29
310	Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. *Genes Chromosomes and Cancer*, **2016**, 55, 418-27	5	29
309	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. *Acta Neuropathologica*, **2018**, 136, 293-302	14.3	29
308	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. *Acta Neuropathologica*, **2014**, 128, 449-52	14.3	28
307	No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. *International Journal of Cancer*, **2004**, 109, 476-9	7.5	28
306	Analysis of TP53 and PTEN in gliomatosis cerebri. *Acta Neuropathologica*, **2003**, 105, 529-36	14.3	28
305	Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. *Genes Chromosomes and Cancer*, **2005**, 44, 161-9	5	28
304	Evidence for subarachnoid spread in the development of multiple meningiomas. *Brain Pathology*, **1995**, 5, 11-4	6	28
303	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. *Oncotarget*, **2017**, 8, 11460-11479	3.3	28
302	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. *Acta Neuropathologica*, **2019**, 137, 837-846	14.3	28
301	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathologica*, **2019**, 138, 295-308	14.3	27
300	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. *Neuro-Oncology*, **2018**, 20, 826-837	1	27
299	Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. *Journal of Neuro-Oncology*, **2010**, 98, 11-9	4.8	27
298	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. *Journal of Clinical Investigation*, **2015**, 125, 593-606	15.9	27
297	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. *Molecular and Cellular Proteomics*, **2019**, 18, 1255-1268	7.6	26

296	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathologica*, **2020**, 140, 409-413	14.3	26
295	Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. *Cancer*, **2006**, 107, 1365-72	6.4	26
294	Alterations of cell cycle regulators in gliomatosis cerebri. *Journal of Neuro-Oncology*, **2005**, 72, 115-22	4.8	26
293	A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors. *Diagnostic Molecular Pathology*, **1996**, 5, 147-50		26
292	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. *Oncotarget*, **2016**, 7, 14551-68	3.3	26
291	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. *Clinical Cancer Research*, **2019**, 25, 1851-1866	12.9	26
290	Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. *Clinical Sarcoma Research*, **2019**, 9, 2	2.5	25
289	Expression of BRAF V600E mutant protein in epithelial ovarian tumors. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 159-64	1.9	25
288	Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. *International Journal of Cancer*, **2004**, 108, 839-44	7.5	25
287	Analysis of the MEN1 gene in sporadic pituitary adenomas. *Journal of Pathology*, **1999**, 188, 168-73	9.4	25
286	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. *Brain Pathology*, **2016**, 26, 199-205	6	25
285	EGFL7 enhances surface expression of integrin □to promote angiogenesis in malignant brain tumors. *EMBO Molecular Medicine*, **2018**, 10,	12	24
284	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. *Neuro-Oncology*, **2018**, 20, 1517-1524	1	24
283	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. *Acta Neuropathologica*, **2019**, 138, 827-835	14.3	24
282	A Novel Splice Site Associated Polymorphism in the Tuberous Sclerosis 2 (TSC2) Gene May Predispose to the Development of Sporadic Gangliogliomas. *Journal of Neuropathology and Experimental Neurology*, **1997**, 56, 806-810	3.1	24
281	Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. *Acta Neuropathologica*, **2007**, 113, 683-93	14.3	24
280	YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathologica*, **2020**, 139, 215-218	14.3	24
279	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. *Acta Neuropathologica*, **2019**, 137, 521-525	14.3	24

278	The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. *PLoS ONE*, **2010**, 5, e11858	3.7	23
277	Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. *Journal of Neurosurgery*, **2007**, 106, 633-7	3.2	23
276	Rare mutations of the DMBT1 gene in human astrocytic gliomas. *Oncogene*, **2002**, 21, 5956-9	9.2	23
275	Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. *BMC Medicine*, **2016**, 14, 170	11.4	23
274	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. *Clinical Cancer Research*, **2019**, 25, 253-265	12.9	23
273	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. *Neuro-Oncology*, **2020**, 22, 1162-1172	1	22
272	Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model. *Journal of NeuroInterventional Surgery*, **2018**, 10, 268-274	7.8	22
271	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. *Genes Chromosomes and Cancer*, **2009**, 48, 229-38	5	22
270	Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions. *Acta Neuropathologica*, **1997**, 93, 93-6	14.3	22
269	Accumulation of genomic aberrations during clinical progression of medulloblastoma. *Acta Neuropathologica*, **2008**, 116, 383-90	14.3	22
268	Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS. *Regulatory Peptides*, **2007**, 142, 52-9		22
267	Brain slice invasion model reveals genes differentially regulated in glioma invasion. *Biochemical and Biophysical Research Communications*, **2005**, 336, 1227-33	3.4	22
266	A case history of glioma progression. *Acta Neuropathologica*, **1999**, 97, 525-32	14.3	22
265	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. *Neuro-Oncology*, **2021**, 23, 34-43	1	22
264	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. *Cancer Discovery*, **2021**, 11, 2764-2779	24.4	22
263	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. *Journal of Clinical Oncology*, **2020**, 38, 2028-2040	2.2	21
262	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. *Acta Neuropathologica Communications*, **2018**, 6, 21	7.3	21
261	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. *Clinical Cancer Research*, **2018**, 24, 2951-2962	12.9	21

260	Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. *Cancer Research*, **2019**, 79, 4994-5007	10.1	21
259	Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer. *Histopathology*, **2014**, 65, 684-92	7.3	21
258	MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. *Oncotarget*, **2016**, 7, 66344-66359	3.3	21
257	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. *The Lancet Child and Adolescent Health*, **2020**, 4, 121-130	14.5	21
256	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. *Journal of Molecular Diagnostics*, **2016**, 18, 370-377	5.1	21
255	Radiotherapy plus concomitant temozolomide in primary gliosarcoma. *Journal of Neuro-Oncology*, **2016**, 128, 341-8	4.8	21
254	Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. *Nature Communications*, **2021**, 12, 1014	17.4	21
253	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. *Acta Neuropathologica*, **2017**, 134, 965-967	14.3	20
252	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. *Journal of Neuro-Oncology*, **2016**, 129, 319-28	4.8	20
251	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	20
250	Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. *Translational Oncology*, **2013**, 6, 685-96	4.9	20
249	Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS. *PLoS ONE*, **2013**, 8, e57152	3.7	20
248	The evolution of our understanding on glioma. *Brain Pathology*, **2008**, 18, 455-63	6	20
247	Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. *Acta Neuropathologica*, **2005**, 110, 306-11	14.3	20
246	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. *Acta Neuropathologica*, **2020**, 139, 243-257	14.3	20
245	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. *Cancer Discovery*, **2021**, 11, 2230-2247	24.4	20
244	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. *Acta Neuropathologica*, **2017**, 134, 155-158	14.3	19
243	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. *International Journal of Oncology*, **2012**, 40, 2058-62	4.4	19

242	Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. *Brain Pathology*, **2013**, 23, 311-8	6	19
241	Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. *International Journal of Cancer*, **1997**, 74, 322-5	7.5	19
240	Clonal analysis in glioblastoma with epithelial differentiation. *Brain Pathology*, **2001**, 11, 39-43	6	19
239	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 97-104	4.9	19
238	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. *Acta Neuropathologica Communications*, **2019**, 7, 163	7.3	18
237	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. *Seminars in Neurology*, **2018**, 38, 19-23	3.2	18
236	Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. *Clinical Neurology and Neurosurgery*, **2016**, 142, 72-80	2	18
235	Intraoperative radiofrequency ablation of lung metastases and histologic evaluation. *Annals of Thoracic Surgery*, **2009**, 87, 379-84	2.7	18
234	Granulomatous tissue response in germinoma, a diagnostic pitfall in endoscopic biopsy. *Neuropathology*, **2007**, 27, 127-32	2	18
233	DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. *Clinical Cancer Research*, **2020**, 26, 93-100	12.9	18
232	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. *Acta Neuropathologica*, **2017**, 134, 297-316	14.3	17
231	Identification of KIF11 As a Novel Target in Meningioma. *Cancers*, **2019**, 11,	6.6	17
230	Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. *Oncotarget*, **2015**, 6, 13579-90	3.3	17
229	Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. *International Journal of Cancer*, **2012**, 131, 1963-8	7.5	17
228	Somatic mitochondrial mutations in pilocytic astrocytoma. *Cancer Genetics and Cytogenetics*, **2009**, 192, 30-5		17
227	Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. *International Journal of Cancer*, **2003**, 106, 74-7	7.5	17
226	Infratentorial IDH-mutant astrocytoma is a distinct subtype. *Acta Neuropathologica*, **2020**, 140, 569-581	14.3	17
225	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.. *Nature Cancer*, **2021**, 2, 723-740	15.4	17

224	Diagnostic accuracy of DW MR imaging in the differentiation of chordomas and chondrosarcomas of the skull base: A 3.0-T MRI study of 105 cases. *European Journal of Radiology*, **2018**, 105, 119-124	4.7	17
223	Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. *Journal of Neurosurgery*, **2018**, 128, 1102-1114	3.2	16
222	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. *Molecular and Cellular Proteomics*, **2018**, 17, 2132-2145	7.6	16
221	Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. *Journal of Neuro-Oncology*, **2019**, 145, 469-477	4.8	15
220	Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. *Leukemia Research*, **2010**, 34, 1091-3	2.7	15
219	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. *Journal of Clinical Oncology*, **2018**, 36, 2001-2001	2.2	15
218	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. *Oncotarget*, **2016**, 7, 82028-82045	3.3	15
217	Differential nuclear ATRX expression in sarcomas. *Histopathology*, **2016**, 68, 738-45	7.3	15
216	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. *Molecular Cancer Research*, **2018**, 16, 767-776	6.6	14
215	Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 1573-1584	8.8	14
214	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. *Clinical Cancer Research*, **2018**, 24, 4494-4504	12.9	14
213	Defective p53 antiangiogenic signaling in glioblastoma. *Neuro-Oncology*, **2010**, 12, 894-907	1	14
212	Molecular pathology of oligodendroglial tumors. *Recent Results in Cancer Research*, **2009**, 171, 25-49	1.5	14
211	The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. *Oncology Research*, **2010**, 18, 469-80	4.8	14
210	Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. *Human Genetics*, **2001**, 108, 409-15	6.3	14
209	Clonal origin of recurrent meningiomas. *Brain Pathology*, **1999**, 9, 645-50	6	14
208	T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. *Neuro-Oncology Advances*, **2020**, 2, vdaa004	0.9	14
207	Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. *Brain Pathology*, **2020**, 30, 213-225	6	14

206	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. *Acta Neuropathologica*, **2021**, 141, 85-100	14.3	14
205	Proteomics in Pathology. *Proteomics*, **2018**, 18, 1700361	4.8	14
204	Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. *Journal of Medicinal Chemistry*, **2018**, 61, 8981-9003	8.3	14
203	Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. *Acta Neuropathologica Communications*, **2019**, 7, 140	7.3	13
202	Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis. *Journal of Neuro-Oncology* , **2015**, 124, 265-73	4.8	13
201	Nbn and atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye. *PLoS ONE*, **2013**, 8, e69209	3.7	13
200	LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. *International Journal of Cancer*, **2016**, 139, 424-32	7.5	13
199	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. *Neuro-Oncology*, **2019**, 21, 214-221	1	13
198	G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. *Cell*, **2021**, 184, 655-674.e27	36.2	13
197	Extra-small dual-lumen micro-balloon catheters can improve endovascular embolization: an experimental in vivo and in vitro study. *Journal of NeuroInterventional Surgery*, **2018**, 10, 1092-1096	7.8	12
196	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. *Histopathology*, **2011**, 58, 1167-72	7.3	12
195	Assessment of tumor cell invasion factors in gliomatosis cerebri. *Journal of Neuro-Oncology*, **2005**, 73, 109-15	4.8	12
194	Clinical neuropathology practice news 2-2012: BRAF V600E testing **2012**, 31, 64-6		12
193	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. *Acta Neuropathologica*, **2020**, 139, 277-286	14.3	12
192	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. *Cancers*, **2019**, 11,	6.6	11
191	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. *Glia*, **2015**, 63, 1850-9	9	11
190	Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. *Modern Pathology*, **2009**, 22, 1263-71	9.8	11
189	Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region. *Journal of Pediatric Hematology/Oncology*, **2010**, 32, 156-9	1.2	11

188	Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. *Journal of Neuro-Oncology*, **2008**, 86, 23-30	4.8	11
187	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chromosomes and Cancer*, **2000**, 29, 16-25	5	11
186	The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells. *Oncology Research*, **2009**, 18, 95-105	4.8	11
185	Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study. *Journal of Nuclear Medicine*, **2021**,	8.9	11
184	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. *Acta Neuropathologica*, **2017**, 133, 325-327	14.3	10
183	Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. *Frontiers in Neuroscience*, **2018**, 12, 1004	5.1	10
182	Endometrial stromal sarcomas with BCOR-rearrangement harbor MDM2 amplifications. *Journal of Pathology: Clinical Research*, **2020**, 6, 178-184	5.3	10
181	A PRDX1-p38 heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas. *International Journal of Cancer*, **2018**, 143, 1176-1187	7.5	10
180	IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. *Haematologica*, **2010**, 95, 1797-8	6.6	10
179	Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. *Journal of Molecular Histology*, **2008**, 39, 553-60	3.3	10
178	Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 40-5	3.1	10
177	Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. *Acta Neuropathologica*, **2020**, 140, 881-891	14.3	10
176	Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. *Acta Neuropathologica*, **2020**, 140, 893-906	14.3	10
175	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. *Brain Pathology*, **2016**, 26, 506-16	6	10
174	Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas - Imaging analysis and histological validation. *Radiotherapy and Oncology*, **2021**, 160, 192-201	5.3	10
173	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). *Acta Neuropathologica*, **2018**, 136, 303-313	14.3	9
172	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO and Shakespeare. *Acta Neuropathologica*, **2017**, 134, 517-520	14.3	9
171	Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 655-664	3.1	9

170	Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression **2005**, 27, 1029		9
169	Pdgfr-alpha in 1p/19q LOH oligodendrogliomas. *International Journal of Cancer*, **2004**, 112, 1081-2	7.5	9
168	No preferential loss of paternal 19q alleles in oligodendroglial tumors. *Annals of Neurology*, **2003**, 54, 256-8	9.4	9
167	Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas. *Acta Neuropathologica*, **2005**, 109, 314-20	14.3	9
166	Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. *Journal of Clinical Oncology*, **2014**, 32, 2014-2014	2.2	9
165	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.. *Journal of Clinical Oncology*, **2020**, 38, LBA10503-LBA10503	2.2	9
164	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. *Acta Neuropathologica*, **2021**, 141, 281-290	14.3	9
163	Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. *Experimental and Molecular Pathology*, **2017**, 102, 25-31	4.4	8
162	Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. *Neurosurgery*, **2019**, 85, E722-E729	3.2	8
161	MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. *Archives of Dermatological Research*, **2014**, 306, 873-84	3.3	8
160	No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 426-30	1.9	8
159	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. *Genes Chromosomes and Cancer*, **2009**, 48, 558-68	5	8
158	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. *Journal of Clinical Investigation*, **2020**, 130, 2488-2495	15.9	8
157	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, 2000-2000	2.2	8
156	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. *Journal of Clinical Oncology*, **2021**, 39, 3839-3852	2.2	8
155	Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening. *RSC Advances*, **2016**, 6, 96735-96742	3.7	8
154	Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. *Clinical Cancer Research*, **2019**, 25, 5260-5270	12.9	7
153	Farewell to oligoastrocytoma: response to letters. *Acta Neuropathologica*, **2015**, 129, 155	14.3	7

152	Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival. *Clinical Cancer Research*, **2020**, 26, 2231-2243	12.9	7
151	Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 388-393	2.9	7
150	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. *Cancers*, **2019**, 11,	6.6	7
149	Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma **2012**,		7
148	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. *Blood*, **2016**, 128, 745-745	2.2	7
147	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. *Journal of Clinical Oncology*, **2015**, 33, 2001-2001	2.2	7
146	Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. *Journal of Clinical Oncology*, **2015**, 33, 2006-2006	2.2	7
145	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. *Cancer Medicine*, **2020**, 9, 8373-8385	4.8	7
144	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. *Radiology*, **2020**, 297, 164-175	20.5	7
143	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. *Neuro-Oncology*, **2021**, 23, 1547-1559	1	7
142	Loss of H3K27me3 in meningiomas. *Neuro-Oncology*, **2021**, 23, 1282-1291	1	7
141	Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. *Journal of Neuro-Oncology*, **2018**, 140, 659-667	4.8	7
140	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. *Acta Neuropathologica*, **2021**, 142, 841-857	14.3	7
139	Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 382-8	1.9	6
138	p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. *Cellular Physiology and Biochemistry*, **1997**, 7, 304-311	3.9	6
137	The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. *Journal of Perinatal Medicine*, **2005**, 33, 314-9	2.7	6
136	Analysis of the TSC2 gene in human medulloblastoma. *Acta Neuropathologica*, **2001**, 102, 380-4	14.3	6
135	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. *Acta Neuropathologica*, **2020**, 139, 403-406	14.3	6

134	Kaposiform hemangioendothelioma and tufted angioma - (epi)genetic analysis including genome-wide methylation profiling. *Annals of Diagnostic Pathology*, **2020**, 44, 151434	2.2	6
133	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. *Acta Neuropathologica*, **2020**, 139, 583-596	14.3	6
132	Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: A comparative genome-wide methylation study. *Annals of Diagnostic Pathology*, **2019**, 41, 102-105	2.2	5
131	Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. *Journal of Investigative Dermatology*, **2013**, 133, 1372-5	4.3	5
130	Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. *Acta Neuropathologica*, **1999**, 97, 547-51	14.3	5
129	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. *Journal of Clinical Oncology*, **2016**, 34, TPS2082-TPS2082	2.2	5
128	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. *Acta Neuropathologica*, **2021**, 142, 179-189	14.3	5
127	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. *Modern Pathology*, **2021**, 34, 1558-1569	9.8	5
126	Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. *Acta Neuropathologica Communications*, **2019**, 7, 201	7.3	5
125	Sclerosing epithelioid mesenchymal neoplasm of the pancreas□□a proposed new entity. *Modern Pathology*, **2020**, 33, 456-467	9.8	5
124	Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures. *PLoS ONE*, **2018**, 13, e0205772	3.7	5
123	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. *Acta Neuropathologica*, **2018**, 136, 975-978	14.3	5
122	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. *Acta Neuropathologica*, **2021**, 142, 827-839	14.3	5
121	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.. *Cancer Discovery*, **2021**,	24.4	5
120	Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. *Journal of Neuropathology and Experimental Neurology*, **2019**, 78, 1073-1075	3.1	4
119	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. *Neuro-Oncology*, **2020**, 22, 1667-1676	1	4
118	Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines. *Cancers*, **2020**, 12,	6.6	4
117	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series. *Klinische Padiatrie*, **2018**, 230, 305-313	0.9	4

116	Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II. *Histopathology*, **2009**, 54, 241-7	7.3	4
115	45-year-old male with symptomatic mass in the frontal lobe. *Brain Pathology*, **2006**, 16, 89-90, 93	6	4
114	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NMM).. *Journal of Clinical Oncology*, **2016**, 34, TPS2084-TPS2084	2.2	4
113	Epidermal Nbn deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. *Oncotarget*, **2016**, 7, 23006-18	3.3	4
112	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. *Modern Pathology*, **2021**, 34, 2122-2129	9.8	4
111	RINT1 functions as a multitasking protein at the crossroads between genomic stability, ER homeostasis, and autophagy. *Autophagy*, **2016**, 12, 1413-5	10.2	4
110	FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. *Acta Neuropathologica*, **2020**, 139, 175-192	14.3	4
109	Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. *Gut*, **2021**,	19.2	4
108	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 1472-1480	4	4
107	Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. *Neuro-Oncology*, **2021**,	1	4
106	Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. *Bioorganic and Medicinal Chemistry*, **2017** , 25, 6379-6387	3.4	3
105	Impact of post-surgical freezing delay on brain tumor metabolomics. *Metabolomics*, **2019**, 15, 78	4.7	3
104	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. *Acta Neuropathologica*, **2020**, 140, 237-239	14.3	3
103	Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors. *Langenbeckls Archives of Surgery*, **2020**, 405, 199-205	3.4	3
102	ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. *Neuro-Oncology*, **2017**, 19, vi2-vi2	1	3
101	Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. *Modern Pathology*, **2018**, 31, 160-168	9.8	3
100	BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. *Journal of Investigative Dermatology*, **2018**, 138, 2489-2491	4.3	3
99	Differential concentration-dependent effects of prolonged norepinephrine infusion on intraparenchymal hemorrhage and cortical contusion in brain-injured rats. *Journal of Neurotrauma*, **2003**, 20, 1327-37	5.4	3

98	Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. *Journal of Clinical Oncology*, **2014**, 32, 2017-2017	2.2	3
97	EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. *Journal of Clinical Oncology*, **2016**, 34, 2042-2042	2.2	3
96	VXM01 phase I study in patients with progressive glioblastoma: Final results.. *Journal of Clinical Oncology*, **2018**, 36, 2017-2017	2.2	3
95	-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. *Cell Stress*, **2017**, 1, 55-67	5.5	3
94	Quality assurance in neuropathology: Experiences from the round robin trials on mutation and promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019 **2020**, 39, 203-211		3
93	The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. *Neurosurgical Review*, **2021**, 44, 2707-2715	3.9	3
92	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. *Pathology Research and Practice*, **2020**, 216, 152728	3.4	3
91	Telomerase reverse transcriptase promoter mutation- and O-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. *European Journal of Cancer*, **2021**, 147, 84-94	7.5	3
90	DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the 'DKFZ Sarcoma Classifier'. *Journal of Pathology: Clinical Research*, **2021**, 7, 350-360	5.3	3
89	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. *Neuro-Oncology*, **2021**, 23, 1597-1611	1	3
88	Ectopic intracranial retinoblastoma in a 3.5-month-old infant without eye involvement and without evidence of heritability. *Pediatric Blood and Cancer*, **2019**, 66, e27599	3	3
87	Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation. *International Journal of Cancer*, **2019**, 145, 461-473	7.5	3
86	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. *Neuro-Oncology*, **2021**, 23, 1576-1585	1	3
85	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. *Nature Communications*, **2021**, 12, 5530	17.4	3
84	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. *Acta Neuropathologica*, **2019**, 138, 275-293	14.3	2
83	Molecular progression of SHH-activated medulloblastomas. *Acta Neuropathologica*, **2019**, 138, 327-330	14.3	2
82	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. *Acta Neuropathologica*, **2019**, 137, 847-850	14.3	2
81	Germline SDHB-inactivating mutation in gastric spindle cell sarcoma. *Genes Chromosomes and Cancer*, **2020**, 59, 601-608	5	2

80	Molecular profiling-based decision for targeted therapies in wild-type glioblastoma. *Neuro-Oncology Advances*, **2020**, 2, vdz060	0.9	2
79	Analysis of a Surgical Series of 21 Cerebral Radiation Necroses. *World Neurosurgery*, **2020**, 137, e462-e469	2.1	2
78	PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. *Neuro-Oncology*, **2017**, 19, vi184-vi185	1	2
77	Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. *Neuropathology*, **1998**, 18, 145-153	2	2
76	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.. *Acta Neuropathologica Communications*, **2022**, 10, 5	7.3	2
75	Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. *Journal of Clinical Oncology*, **2014**, 32, 2006-2006	2.2	2
74	VXM01 phase I study in patients with resectable progression of a glioblastoma.. *Journal of Clinical Oncology*, **2017**, 35, 2061-2061	2.2	2
73	DNA methylation-based classification of malformations of cortical development in the human brain. *Acta Neuropathologica*, **2021**, 1	14.3	2
72	Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. *Letters in Drug Design and Discovery*, **2019**, 16, 861-867	0.8	2
71	Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. *Cancer*, **2021**,	6.4	2
70	Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. *Acta Neurochirurgica*, **2020**, 162, 3019-3024	3	2
69	The age of adult pilocytic astrocytoma cells. *Oncogene*, **2021**, 40, 2830-2841	9.2	2
68	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. *Acta Neuropathologica*, **2021**, 141, 971-974	14.3	2
67	Deep Neural Network for Differentiation of Brain Tumor Tissue Displayed by Confocal Laser Endomicroscopy. *Frontiers in Oncology*, **2021**, 11, 668273	5.3	2
66	Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion		2
65	Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. *Modern Pathology*, **2021**, 34, 2043-2049	9.8	2
64	Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. *Cancers*, **2021**, 13,	6.6	2
63	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. *Acta Neuropathologica*, **2019**, 137, 1003-1015	14.3	2

62	Assessment of Melanin Content and its Influence on Susceptibility Contrast in Melanoma Metastases. *Clinical Neuroradiology*, **2020**, 30, 607-614	2.7	2
61	Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. *Neuropathology and Applied Neurobiology*, **2021**, 47, 406-414	5.2	2
60	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. *Acta Neuropathologica Communications*, **2021**, 9, 20	7.3	2
59	Subgroup and subtype-specific outcomes in adult medulloblastoma. *Acta Neuropathologica*, **2021**, 142, 859-871	14.3	2
58	Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. *Journal of Pathology*, **2021**,	9.4	2
57	Prognostic impact of genetic alterations and methylation classes in meningioma.. *Brain Pathology*, **2022**, 32, e12970	6	2
56	Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA.. *European Journal of Cancer*, **2022**, 168, 1-11	7.5	2
55	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. *Neuro-Oncology*, **2019**, 21, ii82-ii82	1	1
54	IDH1 mutant glioma initiating cells are predisposed to apoptosis under endoplasmic reticulum (ER) stress. *Neuro-Oncology*, **2018**, 20, i13-i13	1	1
53	IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA. *Neuro-Oncology*, **2015**, 17, v116.1-v116	1	1
52	Bone marrow biopsies of patients with hematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology. *Pathology Research and Practice*, **2012**, 208, 510-7	3.4	1
51	Analysis of a polymorphism in the tuberous sclerosis (TSC2) gene does not predispose to schizophrenia. *European Archives of Psychiatry and Clinical Neuroscience*, **1998**, 248, 314-5	5.1	1
50	Occurrence of a spinal anaplastic pilocytic astrocytoma and a supratentorial PNET in an adolescent. *Journal of Pediatric Hematology/Oncology*, **2007**, 29, 832-5	1.2	1
49	Laser-assisted microdissection, techniques and applications in pathology (Review). *International Journal of Molecular Medicine*, **2005**, 15, 763	4.4	1
48	Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review) **2003**, 23, 857		1
47	Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. *Journal of Clinical Oncology*, **2015**, 33, 2007-2007	2.2	1
46	Genetic and epigenetic characterization of posterior pituitary tumors. *Acta Neuropathologica*, **2021**, 142, 1025-1043	14.3	1
45	An activating germline variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid.. *Human Genetics and Genomics Advances*, **2020**, 1, 100006	0.8	1

44	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. *Translational Oncology*, **2020**, 13, 100852	4.9	1
43	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. *Journal of Neurochemistry*, **2021**, 158, 522-538	6	1
42	The molecular evolution of glioblastoma treated by gross total resection alone. *Neuro-Oncology*, **2021**, 23, 334-336	1	1
41	Molecular diagnostics in drug-resistant focal epilepsy define new disease entities. *Brain Pathology*, **2021**, 31, e12963	6	1
40	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. *Journal of Molecular Diagnostics*, **2021**, 23, 834-846	5.1	1
39	Intrathecal activation of CD8 memory T cells in IgG4-related disease of the brain parenchyma. *EMBO Molecular Medicine*, **2021**, 13, e13953	12	1
38	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. *Acta Neuropathologica*, **2021**, 142, 1065-1069	14.3	1
37	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. *Theranostics*, **2021**, 11, 9217-9233	12.1	1
36	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. *Acta Neuropathologica Communications*, **2022**, 10, 39	7.3	1
35	Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.. *Journal of Pathology*, **2022**,	9.4	1
34	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease.. *Neuro-Oncology*, **2022**,	1	1
33	GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. *Neuro-Oncology*, **2019**, 21, ii83-ii83	1	0
32	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of. *JCO Precision Oncology*, **2020**, 4,	3.6	0
31	The INFORM personalized medicine study for high-risk pediatric cancer patients.. *Journal of Clinical Oncology*, **2017**, 35, 10509-10509	2.2	0
30	Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. *Brain Pathology*, **2021**, e13037	6	0
29	Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. *Journal of Clinical Oncology*, **2019**, 37, 2057-2057	2.2	0
28	Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippel-Lindau disease-related tumours. *Neuropathology and Applied Neurobiology*, **2021**, 47, 756-767	5.2	0
27	Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes. *Neuro-Oncology Advances*, **2021**, 3, vdab147	0.9	0

26	Rapid-CNS: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study.. *Acta Neuropathologica*, **2022**, 1	14.3	0
25	Oligosarcomas, IDH-mutant are distinct and aggressive.. *Acta Neuropathologica*, **2021**, 143, 263	14.3	0
24	OTHR-41. Amplification of the PLAG family genes PLAGL1 and PLAGL2 is a key feature of a novel embryonal CNS tumor type. *Neuro-Oncology*, **2022**, 24, i156-i156	1	0
23	Report of a Novel Case of Anaplastic Olfactory Groove Meningioma and Its Methylation Subtype. *Journal of Neuropathology and Experimental Neurology*, **2017**, 76, 997-999	3.1	
22	Gliomrezidiv?. *Onkopipeline*, **2009**, 2, 19-22		
21	PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE. *Neuro-Oncology*, **2021**, 23, vi119-vi120	1	
20	NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA. *Neuro-Oncology*, **2021**, 23, vi157-vi157	1	
19	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. *Neuro-Oncology*, **2021**, 23, vi122-vi122	1	
18	BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS. *Neuro-Oncology*, **2021**, 23, vi19-vi19	1	
17	PATH-48. RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY. *Neuro-Oncology*, **2021**, 23, vi126-vi126	1	
16	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. *Neuro-Oncology*, **2021**, 23, vi123-vi124	1	
15	Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. *Journal of Clinical Oncology*, **2018**, 36, 2013-2013	2.2	
14	Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases.. *Journal of Clinical Oncology*, **2018**, 36, e21515-e21515	2.2	
13	Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. *Journal of Clinical Oncology*, **2018**, 36, 12090-12090	2.2	
12	Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. *Journal of Clinical Oncology*, **2019**, 37, 2013-2013	2.2	
11	A Model for the Molecular Pathogenesis of Astrocytic Gliomas **1996**, 173-186		
10	Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme.. *Journal of Clinical Oncology*, **2015**, 33, e13046-e13046	2.2	
9	Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.. *Journal of Clinical Oncology*, **2017**, 35, 2013-2013	2.2	

8	BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. *Blood*, **2012**, 120, 4040-4040	2.2
7	PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE. *Neuro-Oncology*, **2021**, 23, vi125-vi126	1
6	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. *Neuro-Oncology*, **2022**, 24, i107-i107	1
5	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. *Neuro-Oncology*, **2022**, 24, i154-i154	1
4	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. *Neuro-Oncology*, **2022**, 24, i91-i91	1
3	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. *Neuro-Oncology*, **2022**, 24, i91-i92	1
2	LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. *Neuro-Oncology*, **2022**, 24, i90-i90	1
1	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy Results of the MET-HIT2000-BIS4 trial. *Neuro-Oncology*, **2022**, 24, i104-i104	1